미국의 케타민 클리닉 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 치료별, 치료법별, 부문별 예측(2024-2030년)

U.S. Ketamine Clinics Market Growth & Trends:

The U.S. ketamine clinics market size is anticipated to reach USD 6.90 billion by 2030, exhibiting a CAGR of 10.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the increase in mental health awareness, the ongoing opioid crisis, and an increasing number of ketamine clinics across the U.S. According to SAMHSA, in 2022, about 19.86% of adults, which is nearly 50 million people, had some form of mental illness, with 4.91% experiencing severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah.

Moreover, the COVID-19 pandemic had a negative impact on the mental health of adults, leading to an increased demand for innovative treatments. A survey by the Kaiser Family Foundation found that 39.3% of adults in the U.S. reported symptoms of anxiety or depressive disorder in February 2021, a significant increase from pre-pandemic levels. This increase in mental health issues has created the need for effective and rapid treatments, further driving the growth of the market in the U.S.

Moreover, the growing consolidation of local service providers with major ketamine clinic providers to offer ketamine treatments in the U.S. is expected to increase opportunities in the market. Market players are undertaking various strategic initiatives to increase their capabilities, improve competencies, and expand their service portfolios. For instance, in October 2023[, Nue Life Health was acquired by a venture studio specializing in psychedelic healthcare. This acquisition aligned with the studio's mission to advance innovative treatments in the mental wellness space, particularly through the use of psychedelic therapies.

U.S. Ketamine Clinics Market Report Highlights:

• Based on treatment, the depression segment held the largest market share in 2023. This can be attributed to the growing number of American adults burdened with severe major depression.
• Based on therapy, the on-site therapy segment dominated the market with the largest market share in 2023 owing to the growing acceptance of ketamine therapy for mental health disorders which has led to an expansion of clinics in the U.S.
• In February 2024, Avesta Ketamine and Wellness entered into a partnership with Veteran Affairs (VA) to provide free ketamine therapy to veterans across Maryland, Bethesda, Northern Virginia, and Washington DC. This initiative was expected to help veterans with substance abuse disorder, chronic pain, anxiety, PTSD, and treatment-resistant depression.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Volume Price Analysis
• 1.8. Objectives
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. U.S. Ketamine Clinics Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Growing demand for effective mental health treatments
    • 3.3.1.2. Growing acceptance of ketamine's therapeutic potential
    • 3.3.1.3. Increasing investment and partnerships in ketamine clinics
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Potential side effects and risks associated with ketamine therapy
    • 3.3.2.2. Easy accessibility for alternative treatments
• 3.4. Regulatory Framework
• 3.5. Business Environment Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis

Chapter 4. Treatment Business Analysis

• 4.1. U.S. Ketamine Clinics Market: Treatment Movement Analysis
• 4.2. U.S. Ketamine Clinics Market: Treatment Segment Dashboard
• 4.3. Treatment Movement & Market Share Analysis, 2023 & 2030
• 4.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Treatment
• 4.5. Depression
  • 4.5.1. Depression market, 2018 - 2030 (USD Million)
• 4.6. Anxiety
  • 4.6.1. Anxiety market, 2018 - 2030 (USD Million)
• 4.7. PTSD
  • 4.7.1. PTSD market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Therapy Business Analysis

• 5.1. U.S. Ketamine Clinics Market: Therapy Movement Analysis
• 5.2. U.S. Ketamine Clinics Market: Therapy Segment Dashboard
• 5.3. Therapy Movement & Market Share Analysis, 2023 & 2030
• 5.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Therapy
• 5.5. On-site Therapy
  • 5.5.1. On-site therapy market, 2018 - 2030 (USD Million)
• 5.6. Online Therapy
  • 5.6.1. Online therapy market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Company Market Position Analysis
• 6.3. Strategy Mapping
  • 6.3.1. Partnership/Collaboration/Alliance
  • 6.3.2. New Service Launch
  • 6.3.3. Mergers & Acquisitions
  • 6.3.4. Others
• 6.4. Company Profiles/Listing
  • 6.4.1. NY Ketamine Infusions
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Service benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Stella MSO LLC dba Field Trip Health
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Service benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Ketamine Clinics Los Angeles
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Service benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Klarity Clinic (Tebra Inc.)
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Service benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Vitalitas Denver Ketamine Infusion Center
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Service benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Mindbloom, Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Service benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Nue Life Health (NueCo Holdings, P.B.C.)
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Service benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Better U, Inc.
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Service benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Innerwell (KBS, Inc.)
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Service benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Klarisana Health
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Service benchmarking
    • 6.4.10.4. Strategic initiatives